The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview

Abstract

OBJECTIVE The Diabetes Control and Complications Trial (DCCT) was designed to test the glucose hypothesis and determine whether the complications of type 1 diabetes (T1DM) could be prevented or delayed. The Epidemiology of Diabetes Interventions and Complications (EDIC) observational follow-up determined the durability of the DCCT effects on the more-advanced stages of diabetes complications including cardiovascular disease (CVD). RESEARCH DESIGN AND METHODS The DCCT (1982-1993) was a controlled clinical trial in 1,441 subjects with T1DM comparing intensive therapy (INT), aimed at achieving levels of glycemia as close to the nondiabetic range as safely possible, with conventional therapy (CON), which aimed to maintain safe asymptomatic glucose control. INT utilized three or more daily insulin injections or insulin pump therapy guided by self-monitored glucose. EDIC (1994-present) is an observational study of the DCCT cohort. RESULTS The DCCT followed >99% of the cohort for a mean of 6.5 years and demonstrated a 35-76% reduction in the early stages of microvascular disease with INT, with a median HbA1c of 7%, compared with CONV, with a median HbA1c of 9%. The major adverse effect of INT was a threefold increased risk of hypoglycemia, which was not associated with a decline in cognitive function or quality of life. EDIC showed a durable effect of initial assigned therapies despite a loss of the glycemic separation (metabolic memory) and demonstrated that the reduction in early-stage complications during the DCCT translated into substantial reductions in severe complications and CVD. CONCLUSIONS DCCT/EDIC has demonstrated the effectiveness of INT in reducing the long-term complications of T1DM and improving the prospects for a healthy life span.

Figures

Figure 1

Median HbA1c concentrations during DCCT, the “training” period between DCCT and EDIC, and EDIC. P < 0.001 for INT vs. CON during entire DCCT and for the first 3 years during EDIC. Reprinted and modified with permission from Nathan et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study at 30 years: advances and contributions. Diabetes 2013;62:3976–3986.

Figure 2

Summary of reduction in major complications with INT compared with CON during DCCT, EDIC, and combined study periods. 3+step devel, Prim: three-step or more development of retinopathy based on Early Treatment of Diabetic Retinopathy scale (ref. 13) in the primary prevention group. Scnd: secondary intervention group. Microalb: microalbuminuria defined as albumin excretion ≥40 mg/24 h. Macroalb: macroalbuminuria defined as albumin excretion >300 mg/24 h. Reduced GFR: estimated GFR 2. CVD events: CVD including myocardial infarctions, stroke, and CVD death. Reprinted with permission from Nathan et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study at 30 years: advances and contributions. Diabetes 2013;62:3976–3986.